This randomly assigned, neither you nor the study doctors know who gets the real treatment, sham-controlled clinical trial aims to measure the how well it works and underlying biological mechanisms of HD-tDCS targeting the primary somatosensory cortex in adolescents with bipolar depression. you would be randomly assigned to receive either active HD-tDCS or sham stimulation, in addition to routine clinical care.
Official registry: https://clinicaltrials.gov/study/NCT07246044 · Jiangsu Province Nanjing Brain Hospital · enrollment listed as 100
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Active HD-tDCS, Antipsychotics, mood stabilizers, etc., or Sham HD-tDCS. The registry lists allocation as randomized. This randomly assigned, neither you nor the study doctors know who gets the real treatment, sham-controlled clinical trial aims to measure the how well it works and underlying biological mechanisms of HD-tDCS targeting the primary somatosensory cortex in adolescents with bipolar depression.
They plan to enroll about 100 people at Nanjing. Taking part typically means taking a study drug (or dummy pill), using or being fitted with a device plus check-ins.
High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Targeting the Primary Somatosensory Cortex for Bipolar Depression in Adolescents: A Randomized Double-Blind Controlled Trial
Interventions: Active HD-tDCS, Antipsychotics, mood stabilizers, etc., Sham HD-tDCS
Primary outcome (registry wording): Change from baseline in depressive symptoms assessed by the 17-item Hamilton Depression Rating Scale (HAMD-17) at Week 2.
Lifei Wang
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG).
NCT00018057 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)
Background: There are no good treatments for people considering suicide. Researchers want to study suicide with questions, blood tests, brain imaging, and sleep studies.
NCT02543983 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)
The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), and Alzheimer's Disease (AD) as compared to healthy controls Secondary: 1. To assess the relationship between microglial activation and clinical variables including disease severity and comorbidities (such as pain, fatigue and/or depression), as well as clinical MRI findings (such as lesions and atrophy) 2.
NCT02649985 · Official ClinicalTrials.gov record · Brigham and Women's Hospital
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary